Bystryn JC - Search Results

1

Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.

Reynolds SR, Zeleniuch-Jacquotte A, Shapiro RL, Roses DF, Harris MN, Johnston D, Bystryn JC. Reynolds SR, et al. Among authors: bystryn jc. Clin Cancer Res. 2003 Feb;9(2):657-62. Clin Cancer Res. 2003. PMID: 12576432

2

Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma.

Reynolds SR, Albrecht J, Shapiro RL, Roses DF, Harris MN, Conrad A, Zeleniuch-Jacquotte A, Bystryn JC. Reynolds SR, et al. Among authors: bystryn jc. Clin Cancer Res. 2003 Apr;9(4):1497-502. Clin Cancer Res. 2003. PMID: 12684425

3

Melanoma vaccines: what we know so far.

Bystryn JC, Reynolds SR. Bystryn JC, et al. Oncology (Williston Park). 2005 Jan;19(1):97-108; discussion 108, 111-2, 115. Oncology (Williston Park). 2005. PMID: 15743154 Free article. Review.

4

Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?

Reynolds SR, Vergilis IJ, Szarek M, Ferrone S, Bystryn JC. Reynolds SR, et al. Among authors: bystryn jc. Int J Cancer. 2006 Jul 1;119(1):157-61. doi: 10.1002/ijc.21820. Int J Cancer. 2006. PMID: 16450373 Clinical Trial.

5

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma.

Bystryn JC, Oratz R, Roses D, Harris M, Henn M, Lew R. Bystryn JC, et al. Cancer. 1992 Mar 1;69(5):1157-64. doi: 10.1002/cncr.2820690516. Cancer. 1992. PMID: 1739915

6

Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.

Oratz R, Dugan M, Roses DF, Harris MN, Speyer JL, Hochster H, Weissman J, Henn M, Bystryn JC. Oratz R, et al. Among authors: bystryn jc. Cancer Res. 1991 Jul 15;51(14):3643-7. Cancer Res. 1991. PMID: 2065322 Clinical Trial.

7

Immunogenicity of a polyvalent melanoma antigen vaccine in humans.

Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL. Bystryn JC, et al. Cancer. 1988 Mar 15;61(6):1065-70. doi: 10.1002/1097-0142(19880315)61:6<1065::aid-cncr2820610602>3.0.co;2-l. Cancer. 1988. PMID: 3342366

8

Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine.

Miller K, Abeles G, Oratz R, Zeleniuch-Jacquotte A, Cui J, Roses DF, Harris MN, Bystryn JC. Miller K, et al. Among authors: bystryn jc. Cancer. 1995 Jan 15;75(2):495-502. doi: 10.1002/1097-0142(19950115)75:2<495::aid-cncr2820750212>3.0.co;2-s. Cancer. 1995. PMID: 7812920

9

Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.

Reynolds SR, Oratz R, Shapiro RL, Hao P, Yun Z, Fotino M, Vukmanović S, Bystryn JC. Reynolds SR, et al. Among authors: bystryn jc. Int J Cancer. 1997 Sep 17;72(6):972-6. doi: 10.1002/(sici)1097-0215(19970917)72:6<972::aid-ijc9>3.0.co;2-m. Int J Cancer. 1997. PMID: 9378560 Clinical Trial.

10

HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.

Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC. Reynolds SR, et al. Among authors: bystryn jc. J Immunol. 1998 Dec 15;161(12):6970-6. J Immunol. 1998. PMID: 9862732

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217 results

Search Page

Filters